Individual generic drug information

lamivudine

Reference monograph

Part of registered formulation

ABACAVIR SULFATE + LAMIVUDINE

Reference record: Lamivudine
Source: BNF 80 (2020–2021)
Printed source pages: 711, 712
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Lamivudine only.

Indications And Dose

EPIVIR ® ORAL SOLUTION HIV infection in combination with other antiretroviral drugs ▶BY MOUTH ▶Adult: 150 mg every 12 hours, alternatively 300 mg once daily EPIVIR ® TABLETS HIV infection in combination with other antiretroviral drugs ▶BY MOUTH ▶Adult: 150 mg every 12 hours, alternatively 300 mg once daily ZEFFIX ® Chronic hepatitis B infection either with compensated liver disease (with evidence of viral replication and histology of active liver inflammation or fibrosis) when first-line treatments cannot be used, or (in combination with another antiviral drug without cross-resistance to lamivudine) with decompensated liver disease ▶BY MOUTH ▶Adult: 100 mg once daily, patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection

Source page 711

Cautions

Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine

Source page 711

Prescribing And Dispensing Information

Flavours of oral liquid formulations may include banana and strawberry.

Source page 712

Safety

Extracted information for Lamivudine only.

Interactions

→Appendix 1: lamivudine

Source page 711

Side Effects

▶Common or very common Alopecia. arthralgia. cough. fever. gastrointestinal discomfort. hepatic disorders. malaise. muscle complaints. myopathy. nasal disorder ▶Uncommon Thrombocytopenia ▶Rare or very rare Paraesthesia. peripheral neuropathy. pure red cell aplasia ▶Frequency not known Respiratory tract infection. throat complaints

Source page 711

Breast Feeding

Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.

Source page 711

Renal Impairment

Dose adjustments Reduce dose if eGFR less than 50 mL/minute/1.73 m2; consult product literature.

Source page 711

Monitoring Requirements

When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3–6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation— recurrent hepatitis may occur on discontinuation).

Source pages 711, 712

Dose and formulations

Extracted information for Lamivudine only.

Medicinal Forms

There can be variation in the licensing of Infection different medicines containing the same drug. Oral solution EXCIPIENTS: May contain Sucrose ▶Epivir (ViiV Healthcare UK Ltd) Lamivudine 10 mg per 1 ml Epivir 50mg/5ml oral solution | 240 ml P £39.01 Tablet ▶Epivir (ViiV Healthcare UK Ltd) Lamivudine 150 mg Epivir 150mg tablets | 60 tablet P £143.32 DT = £143.32 Lamivudine 300 mg Epivir 300mg tablets | 30 tablet P £157.51 DT = £157.51 ▶Zeffix (GlaxoSmithKline UK Ltd) Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet P £78.09 DT = £74.17

Source page 712

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

150 mg every 12 hours, alternatively 300 mg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Adults

First line only; read the complete Indications and dose section above.

150 mg every 12 hours, alternatively 300 mg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Adults

First line only; read the complete Indications and dose section above.

100 mg once daily, patients receiving

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

lamivudine

Reference monograph

Part of registered formulation

ABACAVIR SULFATE + LAMIVUDINE

Reference record: Lamivudine
Source: BNF 80 (2020–2021)
Printed source pages: 711, 712
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Lamivudine only.

Indications And Dose

Source page 711

Cautions

Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine

Source page 711

Prescribing And Dispensing Information

Flavours of oral liquid formulations may include banana and strawberry.

Source page 712

Safety

Extracted information for Lamivudine only.

Interactions

→Appendix 1: lamivudine

Source page 711

Side Effects

Source page 711

Breast Feeding

Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.

Source page 711

Renal Impairment

Dose adjustments Reduce dose if eGFR less than 50 mL/minute/1.73 m2; consult product literature.

Source page 711

Monitoring Requirements

Source pages 711, 712

Dose and formulations

Extracted information for Lamivudine only.

Medicinal Forms

Source page 712

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

150 mg every 12 hours, alternatively 300 mg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Adults

First line only; read the complete Indications and dose section above.

150 mg every 12 hours, alternatively 300 mg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Adults

First line only; read the complete Indications and dose section above.

100 mg once daily, patients receiving

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 711

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.